Guggenheim raised the firm’s price target on Insmed to $54 from $52 and keeps a Buy rating on the shares after the company reported Q4 results last week. The firm is updating its model and making “modest changes” to its Arikayce and brensocatib sales estimates, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on INSM:
- 3 Best Stocks to Buy Now, 2/26/2024, According to Top Analysts
- Insmed price target raised to $40 from $37 at BofA
- Insmed Strikes $500M Deal with Leerink for Growth and R&D
- Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update
- Insmed reports Q4 EPS ($1.28), consensus ($1.15)
